Cornerstone Capital Management Holdings’s Aratana Therapeutics, Inc. PETX Stock Holding History

Cornerstone Capital Management Holdings’s Portfolio PETX Stock Details PETX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-31,105	Closed	-$164K	–	1395
2017 Q1	$164K	Sell	31,105 -142,288	-82%	-$961K	﹤0.01%	1187
2016 Q4	$1.24M	Buy	173,393 +49,300	+40%	+$399K	0.01%	897
2016 Q3	$1.16M	Buy	+124,093	New	+$1.03M	0.01%	915

Other funds holding PETX

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

AIC

AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return

Cornerstone Capital Management Holdings's PETX Position: Q2 2017 in Review

Cornerstone Capital Management Holdings sold out of Aratana Therapeutics, Inc. (PETX) in Q2 2017, closing a stake of 31,105 shares — an estimated $164K sold.

Cornerstone Capital Management Holdings first reported a position in PETX in Q3 2016 and held it in 3 quarters. The position peaked at $1.24M in Q4 2016. 105 funds tracked by Wall St. Rank hold PETX as of Q2 2017.

Cornerstone Capital Management Holdings reported no remaining Aratana Therapeutics, Inc. position as of Q2 2017 after selling out during the quarter.
Cornerstone Capital Management Holdings sold 31,105 Aratana Therapeutics, Inc. shares in Q2 2017, an estimated $164K.
Cornerstone Capital Management Holdings first reported a position in Aratana Therapeutics, Inc. in Q3 2016 and held it in 3 quarters.
Cornerstone Capital Management Holdings's Aratana Therapeutics, Inc. position peaked at $1.24M in Q4 2016.
105 funds tracked by Wall St. Rank held Aratana Therapeutics, Inc. as of Q2 2017.

Based on Cornerstone Capital Management Holdings's 13F filing for Q2 2017, filed 14 Aug 2017.